SEC Form 4 · accession 0001209191-17-064066
Aravive, Inc. · ARAV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Srinivas Akkaraju
Director
Period of report
Dec 1, 2017
Accepted (ET)
Dec 5, 2017 · 7:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001513818
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Dec 1, 2017 | P | 419,700 | $2.13 | A | 991,129 | I | see footnote |
| Common StockF3,F2 | Dec 4, 2017 | P | 513,872 | $2.21 | A | 1,505,001 | I | see footnote |
| Common StockF2 | Dec 5, 2017 | P | 42,895 | $2.00 | A | 1,547,896 | I | see footnote |
| Common Stock | holding | — | — | — | 14,955 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the weighted average purchase price of the Shares purchased ranging from a low of $1.975 to a high of $2.25 per share. The reporting person undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- F2Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these shares except to the extent of the Reporting Person's pecuniary interest therein.
- F3Represents the weighted average purchase price of the Shares purchased ranging from a low of $2.125 to a high of $2.25 per share. The reporting person undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.